Quote this publication Share Print

TARDYFERON B9 (ferrous sulfate, folic acid), antianaemic

HAEMATOLOGY - FOCUS
Opinions on drugs - Posted on Sep 10 2015

Reason for request

Renewal of inclusion

Does not recommend the continuation of inclusion on the list of reimbursable products.

 

  • TARDYFERON B9 has Marketing Authorisation in the preventive treatment of iron and folic acid deficiencies in pregnant women when an adequate dietary intake cannot be guaranteed.
  • Systematic supplementation is not indicated during pregnancy with a combination of iron and folic acid for the prevention of a possible deficiency.
  • Only proven iron deficiency needs to be treated with iron and folic acid.

Clinical Benefit

Insufficient

-


Therapeutic use

-

-

Contact Us

Évaluation des médicaments